Biology Laboratory Technician Apprentice
About the job
- A Mittlere Reife, Fachhochschulreife, or Abitur with good performance, particularly in natural-science subjects.
- Interest in biology, chemistry, mathematics, biological questions, biotechnological methods, and modern laboratory technology.
- Interest and openness toward preclinical research and work with laboratory animals, including rodents and non-rodents.
- A careful, structured, and responsible working style.
- Good German and English skills, with the ability to present results clearly.
- Interest in using modern information-technology applications and data-processing programs.
- Ability to work experimentally and interest in scientific relationships.
- Conduct laboratory experiments using biochemical and molecular-biological methods and learn various analytical procedures.
- Investigate biological samples, cell cultures, and microorganisms.
- Operate modern analytical and measuring equipment and evaluate experimental results using digital applications.
- Plan experiments, conduct them independently, and document results precisely and reproducibly.
- Assess active substances for efficacy and tolerability while learning about legally regulated preclinical investigations.
- Gain insight into preclinical investigation models, which may include work with laboratory animals depending on the area of application, while following animal-welfare and legal requirements.
- Develop skills in evaluating, interpreting, and presenting scientific results.
- Work according to high quality standards in pharmaceutical research.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget